1/35
Looks like no tags are added yet.
Neutrophils:
type of white blood cell (WBC) and essential component of ______ immune system
responds to invading ______
DIRECTLY attacks _______ and _______
release _______ to produce inflammatory repsonse at site of infection
inate
pathogens
bacteria and fungi
cytokine
what is the parameter describing the number of neutrophils in the body
Absolute Neutrophil Count (ANC)
Neutropenia is ANC less than ______
1500 cells/nL
what is considered severe neutropenia?
ANC less than 500 cells/hl
OR
ANC< 1000 cells/hl AND predicted to decline 500 cells/hl or less over the next 48 hours (2 days)
risk of infection increases with the _____ and ______ or neutropenia
duration and degree
infection risk in the highest in those with _____ and _____ nuetropenia
prior to ________ during hematopeitic cell transplantation
after _____ therapy for acute eleukemia
profound (<100) and prolonged
prior to engraftment
after induction therapy
febrile neutropenia is also called _______ ________
is it considered a medical emergency?
neutropenic fever
YES
what makes someone considered to have febrile neutropenia?
SEVERE neutropenia (<500 or <1000 predicted to decline to <500 in 48 hours)
PLUS
oral temp (38.8C+ = 101F+ )
temperature (38+ or 100.4F+) sustained over an HOUR
is febrile neutropenia a common or rare complication in patients recieving cancer therapy?
which cancers is it more common in?
NO it is common
10-15% of patients with solid tumors
80% patients with hematologic malignancies
epidemiology:
Complications occur in 25-30% of cases in patients with
_______, renal, respiratory, heart failure
mortality rate up to 11%
An important cause of healthcare resource consumption
hypotension
effect of cytotoxic chemotherapy or hematopetic progenitor cells
most important risk factor for infection
neutropenia
what are some factors that predispose patients to infections?
neutropenia
mucousal barrier injury
dysbiosis
effect of cytoxic chemotherapy on epitherlial cells of the MOUTH and GI tract (manifests as _____)
portal of entry for bacteria into the blood stream
mucousal barrier injjury
gut microbiota altered by certain chemotherapy agents
total body irridaiation
antimicrobial prophylaxis- use
colonization with nosocomial organisms such as pseudomonas aerginosa and yeast overgrowth
dysbiosis
Microbiology:
Infectious etiology is identified in only 40- 50%.
Most infections are caused by endogenous/exogenous flora
Gram-positive and Gram-negative ______ are the predominant pathogens
______ are late causes of infection in severely immunocompromised hosts
endogenous flora
bacteria
fungi - late cuases of infection
which gram negative bacteria causes SEVERE infections?
why are gram positive febrile neutropenias frequent?
gram negative = psudomonas aerugonomas
gram positive = central venous catheters + fluroquinolones prophylaxis
what are common gram negative aerobic bacteria?
escherichia coli
klebsiella spp.
psuedomonas auerginosa
other enterobacterales
Clinical Presentation:
_______ is usually the first and ONLY sign of infection
classic signs of infection may be absent due to impaired _______ response
infection can progress ________
fever
inflammatory
rapidly
_____ in the setting of neutropenia is considered a sign of infection until proven otherwise
fever in neutropenia = INFECTION
What are three types of infections?
microbiologically documented infections
clinically documented infections
fever of unknown origin
What are some diagnostic and labroatory testing for Febrile Neutropenia?
CBC with differential
chemistry tests (electrolytes + renal + hepatic)
History and physical examination
Classic signs of infection may be attenuated or absent
Common sites should be assessed
Two sets of blood cultures
chest radiograph
Risk assessment:
predicts probability of ______ __________
Risk stratification concepts
Most patients receiving treatment for ______ _______ are considered LOW RISK (druation of neutropenia < 7 days)
most patients receieving treatment for ________ ________ are considered HIGH RISK (neutropenia for ___ or more days!)
Determines whether or not treatment should be adminsitered ________ or ______
serious complications
LOW RISK = Solid tumors (neutropenia less than 7 days)
HIGH RISK = Hematologic malignancies (neutropenia for more than 7 days)
Inpatient or outpatient
Low-Risk (ALL of the following must be present):
MASC score ___+ or CISNE less than _____
_____ status
NO associated ______ ilness requiring hopsitalizations
anticipated short duration of severe neutropenia (less than __ days)
good preformance status of ________
no ______ or _____ insufficiency
MASC 21+ CISNE less than 3+
outpatient
comorbid
7 days
ECOG 0-1
heaptic or renal
High-Risk (1+ of these present):
MASCC less than ___ or CISNE greater than ____
______ status
significant _____ illness or clinically unstable
anticipated prolonged of severe neutropenia (____ or more days)
uncontrolled/progessive cancer
________ or other complex infections at clinical presentation
_______ or hematologic malignancy
less than 21 or 3+
inpatient
comorbid
7+ days of neutropenia
pneumonia
HSCT (hematopoietic stem cell transplantation)
High-risk patients (MASC <21 and CISNE 3+)
Require _________ and IV _________
Low- risk patients (MASC 21+ and CISNE < 3)
may be treated in the outpatient setting with _____ or _____ _________ if no logistical barriers such as
residence in close proximity to a medical facility
family member or caregiver at home
access to a telephone + transportation
High risk
hospitalizations and IV antimicrobials
Low risk:
PO or IV antimicrobials
Principles of Antimicrobial Therapy:
_____ in a patient with neutropenia from cancer therapy should be assumed to be due to infection until proven otherwise
patients should be assesed soon (within ___ minutes) after presenting with febrile neutrotoxicity
first dose of empiric antimicrobials should be administered within ____ minutes
empirical antimicrobials regimens should ALWAYS cover ______ _______
fever
within 15 minutes
60 minutes
psuedomonas aeuroginosa
Empiricic therapy in high risk patients:
monotherapy of IV anti- _________ _____________ such as
_________
_________
__________
___________
anti-psuedomonal BETA-LACTAM
pip/tazo (zosyn)
cefepime
meropenen
imipenem/cilastin
HIGH RISK antibiotics:
Choice of beta-lactam guided by previous infection, current symtoms, and institutional antibiogram
regimens with ______ activity IF patient is experiencing abdominal pain or diarhea
_______ preffered if colonized with ESBL producing enterobacteriales
anaerobic activity
carbapenems
HIGH risk antibiotics:
Is vancomycin recommended as a standard part of the initial antibiotic regimen?
why or why not?
NO; consider it ONLY if specific clinical indications NOT empirically
will NOT imporve survival + gram + vacteremias rarely cause rapid demise in patients with febrile neutropenia EXCEPT viridans group streptococcus
vacomycin could increase risk of RESISTANCE and NEPHROTOXICITY
When WOULD you add vancomycin to high risk patient therapy if not empirically?
colonization with MRSA or penecillin resistance streptococus pneumonae
skin and soft-tissue infection
pneumonia
catheter IV related infection
blood culture POSITIVE for GRAM POSITIVE bacrteia before final identification and suceptibilties
clinical INSTABILITY (hypotension, shock)
Empiric Therapy in LOW risk Patients:
first does of IV antimicrobials administered in medical facility
choice of IV antimicrobials simmilar to high risk partients (anti-psuedomonal beta lactam)
observed for __+ hours before discharge
transitions to PO_________ based regimen on discharge
observed for 4+ hours before discharge
trasntition from IV antipsuedomonal beta lactam —> PO fluroquinolone on discharge
PO fluoroquinolone examples:
ciprofloxacin + amoxicillin clavulanate (preferred)
ciprofloxacin + clindamycin
levofloxicin
moxifloxacin
Can low risk patients be given PO fluroquinolones upon discharge if they have recieved fluroquinolone prophylaxis?
NO
Follow-up therapy HIGH RISK:
vancomycin (if inititated) can be discontinued after ___ _____ if no resistant gram-positive organisms
Patients who become hemodynamically unstable should have their antimicrobial regimens broaded/ more specific
Empiric fungal therapy considered for patients with persistent fever of ____- ____ days
48 hours
Broader if becomes hemodynamically unstable
4-7 days
Follow-up therapy LOW RISK:
outpatients do not devervesce (recompensate fever) after ___- ____ hours of antibiotics may require hospitalization
48 -72 hours
2-3 days
Duration of Therapy:
Microbiologically active or clinically documented infections=
treatment is continued until a standard course of therapy has been completed and ANC is greater than _______ cells/hL
Fever Of Unknown Origin:
treatment continued until afebrile for ___+ days and ANC is _____+ cells/hL
Treatment discontinued after __+ of IV antibiotics and afebrile for __+ days irrespective of ANC (± transition to fluroquinolone prophylaxis)
microbiologically active
500+
fever of unknown origin
2+ days AND ANC 500+ OR
3+ days of antibiotics and afebrile for 2+ days REGARDLESS of ANC (± trasntiiton to fluroquinolone prophylaxis)
Summary:
febrile neutropenia (neutropenic fever) is a ______ ______
______ is often the ONLY sign of infection which can progress RAPIDLY
empiric therapy in high risk patients consists of an ____ __________ ________
_______ is only added added in high risk patients in speicifc clinical situations
Empiric therapy in LOW RISK paitents —> _____ ________
medical emergency
fever
high risk empiric = anti- psuedomonal beta lactam
vancomycin
PO fluroquinolones (cirpofloxacin + amoxicillin clavulonate)